Brokerages predict that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will post $52.97 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Tabula Rasa HealthCare’s earnings. The lowest sales estimate is $52.50 million and the highest is $54.38 million. Tabula Rasa HealthCare posted sales of $33.27 million during the same quarter last year, which would indicate a positive year over year growth rate of 59.2%. The company is expected to issue its next quarterly earnings report on Monday, November 5th.
On average, analysts expect that Tabula Rasa HealthCare will report full-year sales of $198.29 million for the current financial year, with estimates ranging from $195.00 million to $203.28 million. For the next financial year, analysts expect that the business will report sales of $244.53 million, with estimates ranging from $230.30 million to $264.93 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.12. The firm had revenue of $48.60 million during the quarter, compared to the consensus estimate of $46.73 million. Tabula Rasa HealthCare had a positive return on equity of 4.55% and a negative net margin of 16.78%.
A number of research firms recently weighed in on TRHC. BidaskClub downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 15th. Robert W. Baird boosted their target price on Tabula Rasa HealthCare from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, June 18th. Piper Jaffray Companies boosted their target price on Tabula Rasa HealthCare to $71.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $74.00 target price for the company in a research report on Saturday, August 11th. Finally, Stifel Nicolaus began coverage on Tabula Rasa HealthCare in a research report on Tuesday, September 11th. They issued a “hold” rating and a $95.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $69.75.
NASDAQ:TRHC opened at $81.19 on Friday. The company has a market capitalization of $1.61 billion, a P/E ratio of -2,029.75, a PEG ratio of 6.00 and a beta of 2.71. Tabula Rasa HealthCare has a 1-year low of $24.24 and a 1-year high of $91.16. The company has a quick ratio of 0.33, a current ratio of 0.36 and a debt-to-equity ratio of 0.11.
In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $79.80, for a total value of $638,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 48,000 shares of company stock valued at $3,473,920 in the last 90 days. 14.00% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in TRHC. BlackRock Inc. increased its stake in Tabula Rasa HealthCare by 284.6% in the 1st quarter. BlackRock Inc. now owns 1,634,528 shares of the company’s stock worth $63,419,000 after purchasing an additional 1,209,501 shares during the period. NN Investment Partners Holdings N.V. purchased a new position in Tabula Rasa HealthCare in the 2nd quarter worth approximately $29,439,000. Granite Investment Partners LLC increased its stake in Tabula Rasa HealthCare by 1,969.2% in the 2nd quarter. Granite Investment Partners LLC now owns 212,010 shares of the company’s stock worth $13,532,000 after purchasing an additional 201,764 shares during the period. Braun Stacey Associates Inc. increased its stake in Tabula Rasa HealthCare by 199.0% in the 2nd quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock worth $19,219,000 after purchasing an additional 200,394 shares during the period. Finally, Jennison Associates LLC increased its stake in Tabula Rasa HealthCare by 29.5% in the 2nd quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock worth $48,373,000 after purchasing an additional 172,693 shares during the period. 75.15% of the stock is currently owned by institutional investors and hedge funds.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.